Predictive Factors for Persistent Use and Compliance of Immediate-Release Methylphenidate: A 36-Month Naturalistic Study
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
AIM: The objective of this study was to evaluate predictors of long-term adherence to treatment with methylphenidate (MPH). METHODS: A total of 134 children (ages 4-16) with a diagnosis of attention-deficit/hyperactivity disorder (ADHD) determined by specific protocols, including a semistructured parent interview, Conners' Teacher/Parent Rating Scales, cognitive and learning evaluation, and child self-reports for anxiety and depression, were assessed monthly for up to 36 months. At the end of the study (36 months), three outcomes were evaluated (continuing medication, medication withdrawn due to functional remission, and medication withdrawn for other reasons including poor compliance). Outcomes were first analyzed by mean of the chi-squared test, Mann-Whitney-U test, or t-test, and predictive models were subsequently generated using Cox proportional hazards model analysis. Age, ADHD subtype, co-morbidity, cognitive functioning, side effects, and family and social characteristics were considered as independent variables. RESULTS: Thirty-six months after starting MPH, 62 children (46%) were still on treatment, 32 (24%) had stopped MPH due to functional remission, and 40 (30%) had suspended MPH for other reasons. Within the last group, 20 suspended for poor compliance, 10 for decrease of efficacy, 5 for side effects, and 5 because they entered in an atomoxetine clinical trial. The presence of associated disorders, younger age, female gender, and not living with both parents were predictors for continuing medication until end of the study (36 months); absence of associated disorders and older age were predictors of discontinuation medication due to functional remission before the end of study, older age, and hyperactive subtype were predictors of discontinuing medication for other reasons. CONCLUSION: Clinical outcome of ADHD treatment is heterogeneous: Specific clinical and social predictive parameters for long-term MPH use and compliance can be identified. An accurate tailoring of clinical intervention to the individual child appears crucial for good outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346
A Children's Global Assessment Scale (CGAS)
Shaffer, D. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790100074010 · Cited by 3,716 · cited 4×
“At this time, global functioning was assessed with the Children’s Global Assessment Scale (CGAS) (Shaffer et al. 1983) and degree of symptom improvement was assessed with the Clinical Global Impressions–Improvement score (CGI-I) (Guy 1976); severity of persisting symptoms was also assessed every…”
Influential(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
FARAONE, S. V., BIEDERMAN, J., & MICK, E. (2006) · Psychological Medicine · doi:10.1017/s003329170500471x · Cited by 2,267
The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity
MARCH, J. S., PARKER, J. D. A., SULLIVAN, K., STALLINGS, P., & CONNERS, C. K. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199704000-00019 · Cited by 2,236 · cited 2×
“The child assessment also included self-report measures of anxiety (Multidimensional Anxiety Scale for Children [MASC]) (March et al. 1997) and depression (Children Depression Inventory [CDI]) (Kovacs 1992).”
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Young Adult Outcome of Hyperactive Children: Adaptive Functioning in Major Life Activities
Barkley, R. A., Fischer, M., Smallish, L., & Fletcher, K. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000189134.97436.e2 · Cited by 1,027 · cited 5×
“Untreated, it can have a debilitating impact on normal development, with affected children more likely to experience school failure, poor peer relationship, and familial conflict (Barkley et al. 2004; Barkley et al. 2006; Biederman et al. 2006).”
InfluentialBIEDERMAN, J., MONUTEAUX, M. C., MICK, E., SPENCER, T., WILENS, T. E., SILVA, J. M., SNYDER, L. E., & FARAONE, S. V. (2006) · Psychological Medicine · doi:10.1017/s0033291705006410 · Cited by 850
European clinical guidelines for hyperkinetic disorder ? first upgrade
Taylor, E., D�pfner, M., Sergeant, J., Asherson, P., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Rothenberger, A., Sonuga-Barke, E., et al. (2004) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-004-1002-x · Cited by 682 · cited 1×
“…to international guidelines, treatment for ADHD is based on a multimodal approach that combines behavioral (with a variety of psychosocial interventions, especially efficacious for the management of often associated ODD or CD) and pharmacological treatment (Taylor et al. 2004; Pliszka 2007).”
Self-citationYoung adult follow‐up of hyperactive children: antisocial activities and drug use
Barkley, R. A., Fischer, M., Smallish, L., & Fletcher, K. (2004) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2004.00214.x · Cited by 567
Gillberg, C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830210105014 · Cited by 340
Stimulant treatment over five years: adherence, effectiveness, and adverse effects
Charach, A., Ickowicz, A., & Schachar, R. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200405000-00009 · Cited by 315
Becker, A., Hagenberg, N., Roessner, V., Woerner, W., & Rothenberger, A. (2004) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-004-2004-4 · Cited by 269
Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD
THIRUCHELVAM, D., CHARACH, A., & SCHACHAR, R. J. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200108000-00014 · Cited by 172 · cited 9×
“…al. 2006), male gender (Firestone 1982), lower intelligence quotient (IQ) (Firestone 1982; Brown et al. 1985), more severe ADHD (Charach et al. 2004), oppositional-defiant symptoms (Thiruchelvam et al. 2001), lower socioeconomic status (Ibrahim 2002), and three-times-daily regimen (Gau et al. 2006).”
InfluentialCorkum, P., Rimer, P., & Schachar, R. (1999) · The Canadian Journal of Psychiatry · doi:10.1177/070674379904401011 · Cited by 164 · cited 1×
“Corkum et al. 1999), but decreased to 52–56% after 3 years and to 46% after 5 years of less intensive care (i.e., annual evaluation).”
Continuity of Methylphenidate Treatment for Attention-Deficit/Hyperactivity Disorder
Marcus, S. C., Wan, G. J., Kemner, J. E., & Olfson, M. (2005) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.159.6.572 · Cited by 163 · cited 5×
“Retrospective, population-based studies, on the other hand, showed that after excluding patients with a prescription duration of less than a week, persistence on treatment after 1 year was approximately 15%; less than 50% of the patients continued medication for more than 3–10 months and less than 20% continued medica…”
InfluentialSwanson, J. (2003) · CNS Drugs · doi:10.2165/00023210-200317020-00004 · Cited by 162
Gau, S. S. F., Shen, H.-Y., Chou, M.-C., Tang, C.-S., Chiu, Y.-N., & Gau, C.-S. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.286 · Cited by 148 · cited 4×
“Studies on persistence suggest that predictors of poor adherence to medication may include older age (Thiruchelvam et al. 2001; Gau et al. 2006), male gender (Firestone 1982), lower intelligence quotient (IQ) (Firestone 1982; Brown et al.”
InfluentialFactors associated with children's adherence to stimulant medication
Firestone, P. (1982) · American Journal of Orthopsychiatry · doi:10.1111/j.1939-0025.1982.tb01431.x · Cited by 143
Cited by
Young, S., Adamo, N., Ásgeirsdóttir, B. B., Branney, P., Beckett, M., Colley, W., Cubbin, S., Deeley, Q., Farrag, E., Gudjonsson, G., et al. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02707-9 · Cited by 610
Storebø, O. J., Pedersen, N., Ramstad, E., Kielsholm, M. L., Nielsen, S. S., Krogh, H. B., Moreira-Maia, C. R., Magnusson, F. L., Holmskov, M., Gerner, T., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012069.pub2 · Cited by 321
Improving Medication Adherence in Chronic Pediatric Health Conditions: A Focus on ADHD in Youth
Chacko, A., H. Newcorn, J., Feirsen, N., & Z. Uderman, J. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791959908 · Cited by 66
Fu, D., Wu, D.-D., Guo, H.-L., Hu, Y.-H., Xia, Y., Ji, X., Fang, W.-R., Li, Y.-M., Xu, J., Chen, F., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.780921 · Cited by 66
Achieving Remission as a Routine Goal of Pharmacotherapy in Attention-Deficit Hyperactivity Disorder
Ramos-Quiroga, J. A., & Casas, M. (2011) · CNS Drugs · doi:10.2165/11538450-000000000-00000 · Cited by 33
Metadata
- Authors
- Atzori, P., Usala, T., Carucci, S., Danjou, F., & Zuddas, A.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2009-12
- Volume
- 19
- Issue
- 6
- Pages
- 673-681
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2087584801
- Cited by
- 72
- References
- 19
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.